Skip to main content

Table 1 Percentages of EGI-1 in each phase of the cell cycle after 48 hours of exposure to different dosages of rapamycin

From: Tumor growth effects of rapamycin on human biliary tract cancer cells

Group

Apoptosisa

G0/G1 phase

G2 + M phase

S phase

 

Mean

±SE

P b

Mean

±SE

P b

Mean

±SE

P b

Mean

±SE

P b

control

0.24

0.04

 

32.56

1.01

 

22.44

0.52

 

25.44

0.85

 

rapa 1 ng/mL

0.28

0.02

0.33

35.98

1.21

0.55

21.24

0.35

0.085

17.96

0.23

<0.001

rapa 5 ng/mL

0.30

0.02

0.21

38.77

1.28

<0.05

22.21

0.26

0.70

19.97

0.44

<0.001

rapa 10 ng/mL

0.52

0.04

<0.05

37.09

0.50

<0.05

24.45

0.70

<0.05

15.88

0.29

<0.001

rapa 20 ng/mL

0.55

0.04

<0.05

36.75

1.32

<0.05

23.31

0.45

0.23

14.56

0.33

<0.001

rapa 50 ng/mL

0.42

0.05

<0.05

33.16

0.44

0.60

26.05

0.14

<0.05

16.15

0.37

<0.001

  1. Cell cycle analysis of EGI-1 and TFK-1 cell lines 48 hours after treatment with rapamycin at doses of 1, 5, 10 and 20 ng/mL, with 5-bromo-2′-deoxyuridine and 7-aminoactinomycin D staining aSub G1-region, indicating cells with small DNA fragments, a typical feature of apoptosis; bt-test was performed; while a Levene test was performed in case of unequal variances, P <0.05 was considered significant. Rapa: rapamycin; SE: standard error of the mean.